

ASX ANNOUNCEMENT

23 July 2021

DURAVR™ THV FEATURED PROMINENTLY DURING TVT 2021

Brisbane, Australia and Minneapolis USA, Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company), is pleased to announce that its unique 3D single-piece Transcatheter Heart Valve DurAVR™ THV has been presented in the innovation section of TVT 2021 and was also recognized by the founder and Chairman Emeritus of the Cardiovascular Research Foundation (CRF) which sponsors the Transcatheter Valve Therapies (TVT) Structural Heart Summit to convene leaders in the field to present three days of world-class education and global networking.

The selection process for the innovation award was highly competitive, drawing submissions from large and small companies alike in the TAVR, mitral, tricuspid, and LAA closure (Left Atrial Appendage), spaces.

The innovation presentation was given on behalf of Anteris by Dr. Paul Sorajja, interventional cardiologist and Director of the Center for Valve and Structural Heart Disease where he is the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation, Abbott Northwestern. Dr. Sorajja highlighted the benefits the DurAVR™ THV System brings to patients and heart teams around the world in providing them with an Aortic Valve Replacement that Lasts Longer and Works Better than currently available devices.

In addition to the innovation presentation, Dr. Martin B. Leon, Mallah Family Professor of Cardiology at Columbia University Irving Medical Center and Director of the Center for Interventional Vascular Therapy (CIVT) at New York-Presbyterian/Columbia University Irving Medical Center presented his “top picks” for innovations which will shape the future of TAVR. Dr. Leon is a world renown clinician and a pioneer of the TAVR procedure. During his talk, Dr. Leon discussed several innovative technologies which could shape the future of how Aortic Stenosis will be treated such as machine learning to better diagnose patients, increased treatments rates, and early intervention. TAVR is now firmly established as the standard of care for Aortic Stenosis and will continue its expansion into younger more active patients, underscoring the urgent need for a valve that delivers near normal hemodynamics and durability. DurAVR™ was the only valve technology mentioned in this presentation.

This year’s TVT: Structural Heart Summit was the first in person meeting post COVID-19 restrictions, where Anteris also took the opportunity to meet in person with members of our Medical Advisory Board to demonstrate progress on the DurAVR™ THV and ComASUR™ transfemoral delivery system development program, as well as discuss ongoing preparation for a submission to the US FDA later this year for an Early Feasibility Study.

“The DurAVR™ THV System unlocks the clinical and anatomical challenges that patients are still burdened with in today’s commercially available TAVR devices. DurAVR™ is the beginning of a new era in the next generation of TAVR devices that will last the life of a patient – a critical need in these younger and more active patients. Having DurAVR™ recognized at this very important meeting is a clear demonstration of support for our potential within the Structural Heart Faculty.” said Wayne Paterson, Chief Executive Officer of Anteris.

ENDS

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Trina Raymond
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 420 316 449
www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech